| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to Referees
|
|
|
|
18 |
6 |
p. 803-806
|
artikel
|
| 2 |
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
|
Razak, Albiruni R. Abdul
|
|
|
18 |
6 |
p. 853-868
|
artikel
|
| 3 |
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
|
Peirce, Vivian
|
|
|
18 |
6 |
p. 837-852
|
artikel
|
| 4 |
Back to the Bench: Unveiling the Tissue Context is Crucial to Enhance the Efficacy of Agnostic Therapies in Oncology
|
Ottaiano, Alessandro
|
|
|
18 |
6 |
p. 819-820
|
artikel
|
| 5 |
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status
|
Morimoto, Kenji
|
|
|
18 |
6 |
p. 915-925
|
artikel
|
| 6 |
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
|
Dhamelincourt, Estelle
|
|
|
18 |
6 |
p. 905-914
|
artikel
|
| 7 |
Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
|
Le, Xiuning
|
|
|
18 |
6 |
p. 991
|
artikel
|
| 8 |
Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma
|
Wang, Ning
|
|
|
18 |
6 |
p. 941-952
|
artikel
|
| 9 |
Durvalumab: A Review in Advanced Biliary Tract Cancer
|
Fung, Simon
|
|
|
18 |
6 |
p. 965-972
|
artikel
|
| 10 |
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
|
Zhao, Minmin
|
|
|
18 |
6 |
p. 869-883
|
artikel
|
| 11 |
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
|
Le, Xiuning
|
|
|
18 |
6 |
p. 807-817
|
artikel
|
| 12 |
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers
|
Marchal, Marine
|
|
|
18 |
6 |
p. 927-939
|
artikel
|
| 13 |
Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
|
Poprach, Alexandr
|
|
|
18 |
6 |
p. 893-903
|
artikel
|
| 14 |
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
|
Volta, Francesco
|
|
|
18 |
6 |
p. 953-964
|
artikel
|
| 15 |
Ivosidenib: A Review in Advanced Cholangiocarcinoma
|
Frampton, James E.
|
|
|
18 |
6 |
p. 973-980
|
artikel
|
| 16 |
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
|
De Novellis, Danilo
|
|
|
18 |
6 |
p. 885-892
|
artikel
|
| 17 |
Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer
|
Bylsma, Lauren C.
|
|
|
18 |
6 |
p. 821-835
|
artikel
|
| 18 |
Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma
|
Kang, Connie
|
|
|
18 |
6 |
p. 981-989
|
artikel
|
Tijdschrift beschrijving